COPD Asthma Clinical Trial
Official title:
Identifying Patients With the COPD-Asthma Overlap Phenotype: Therapeutic Implications
Background: Asthma and COPD are considered different diseases but many patients share
characteristics of both entities. This has been termed "COPD-asthma overlap syndrome".
Study objective: To examine: (a) the frequency of the overlap phenotype among patients
referred for pulmonary function testing and, (b) the impact of this phenotype on the
therapeutic management and the quality of life of these patients as compared with patients
with COPD only and asthma only.
Methods:
Type of study: Observational, cross-sectional. Study subjects: Patients referred for
pulmonary function test diagnosed with airway obstruction (FEV1/FVC < 0.7) willing to sign an
informed consent.
Study procedures: Spirometry will be performed before and after the administration of a
bronchodilator. Respiratory questionnaire: Questionnaires about smoking habits, past history
of asthma and wheezing, current medications and history of exacerbations will be administered
at inclusion. Questionnaire on medication utilization will be administered by telephone one
month after inclusion. Quality of life: Will be assessed using the Saint George Respiratory
Questionnaire (SGRQ).
Working definitions: The following definitions will be adopted: a) COPD only: smoking history
> 10 pack/years and post-bronchodilator (BD) FEV1/FVC ratio of < 0.70; b) Asthma only: (1)
presence of wheezing in the last year plus a minimum post-BD increase in FEV1 or FVC of 12%
and 200 ml; (2) prior physician diagnosis (before age 40); and c) both COPD-Asthma (the
overlap group) - the combination of the two.
Outcome measures: The clinical outcome is the prevalence rate of the phenotypes.
Patient-reported outcomes will include the utilization of medication, the number of
exacerbations, and quality of life.
Background: Asthma and COPD are considered different diseases but many patients share
characteristics of both entities. This has been termed "COPD-asthma overlap syndrome".
Study objective: To examine: (a) the frequency of the overlap phenotype among patients
referred for pulmonary function testing and, (b) the impact of this phenotype on the
therapeutic management and the quality of life of these patients as compared with patients
with COPD only and asthma only.
Methods:
Type of study: Observational, cross-sectional. Study subjects: Patients referred for
pulmonary function test diagnosed with airway obstruction (FEV1/FVC < 0.7) willing to sign an
informed consent.
Study procedures: Spirometry will be performed before and after the administration of a
bronchodilator. Respiratory questionnaire: Questionnaires about smoking habits, past history
of asthma and wheezing, current medications and history of exacerbations will be administered
at inclusion. Questionnaire on medication utilization will be administered by telephone one
month after inclusion. Quality of life: Will be assessed using the Saint George Respiratory
Questionnaire (SGRQ).
Working definitions: The following definitions will be adopted: a) COPD only: smoking history
> 10 pack/years and post-bronchodilator (BD) FEV1/FVC ratio of < 0.70; b) Asthma only: (1)
presence of wheezing in the last year plus a minimum post-BD increase in FEV1 or FVC of 12%
and 200 ml; (2) prior physician diagnosis (before age 40); and c) both COPD-Asthma (the
overlap group) - the combination of the two.
Outcome measures: The clinical outcome is the prevalence rate of the phenotypes.
Patient-reported outcomes will include the utilization of medication, the number of
exacerbations, and quality of life.
Statistical plan: Sample size: For an estimated prevalence rate of 20%, 246 patients should
be recruited with 5% imprecision and 95% degree of confidence. To round up, 250 patients will
be included. Statistical methods: Multiple comparisons will be carried out using the one-way
ANOVA for continuous variables and chi-squared test (or Fisher Exact Test) for qualitative
variables. Multiple logistic regression models will be tested to examine the relation between
the "COPD-asthma overlap" phenotype and various independent or predictor variables.
Expected benefits: Data collected could serve to advance the medical community's knowledge
pertaining to the COPD-asthma overlap syndrome. Most importantly, however, they will
encourage reflection on the best therapeutic options for the patients with the overlap
syndrome. Indeed, recommendations on this matter are noticeably absent from the current
guidelines proposed to treat and monitor obstructive lung diseases.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04142827 -
The Effect of Long Term Therapy With High Flow Humidification Compared to Usual Care in Patients With Bronchiectasis (BX)
|
N/A | |
Completed |
NCT05162157 -
Home Spirometry in Primary Care: an Implementation Study
|
||
Not yet recruiting |
NCT03249428 -
E-Cigarette Inner City RCT
|
N/A | |
Recruiting |
NCT05398133 -
Phenotype Assessment of Blood and Airway Eosinophils in Patients With COPD and Asthma
|
||
Recruiting |
NCT03695276 -
Pulmonary Specialist-Health Coach Consult Model Study
|
N/A | |
Completed |
NCT03275935 -
Evaluation of Inhalation Technique in Patients With COPD, Asthma or ACOS Using a Dry Powder Device (DPI)
|
N/A | |
Completed |
NCT05564156 -
Development and Evaluation of Clinical Pharmacy Services in Respiratory Diseases
|
N/A | |
Enrolling by invitation |
NCT03056066 -
Accuracy of Spircare Device as Compared to the Conventional Plethysmograph
|
||
Completed |
NCT03137303 -
Reducing Diagnostic Error to Improve Patient Safety in COPD and Asthma (REDEFINE Study)
|
Phase 3 | |
Not yet recruiting |
NCT05732922 -
ORCHARD- Optimising Home Assessment of Rural Patients
|
N/A | |
Completed |
NCT05397275 -
The Effect of Progressive Relaxation and Breathing Exercise on Sleep Quality and Exercise Self-Efficacy in Patients With COPD
|
N/A | |
Completed |
NCT03739359 -
The Role of Gas Flow in Transnasal Pulmonary Aerosol Delivery: A Double-blinded, Randomized Controlled Trial
|
N/A | |
Completed |
NCT03395418 -
Evaluation of the Right Use of Inhaled Therapeutics
|